Curative Biotechnology Holdings Inc. (OTCMKTS:CUBT) is a molecular diagnostics company founded in 2019 and headquartered in San Dimas, California. Originally established to address urgent public health testing needs, the company rapidly scaled its operations during the COVID-19 pandemic by deploying proprietary nucleic acid amplification and immunoassay platforms. Since then, Curative has broadened its mission to develop and commercialize a range of in vitro diagnostic tools targeting respiratory infections, sexually transmitted infections and other emerging pathogens.
The company’s core business focuses on the development, manufacturing and distribution of point-of-care and high-throughput laboratory tests. Key products include lateral flow immunoassays for rapid antigen detection, reverse transcription-polymerase chain reaction (RT-PCR) kits for molecular confirmation and serological assays for antibody surveillance. Curative operates multiple CLIA-certified laboratories across the United States, enabling seamless sample collection, analysis and digital reporting to healthcare providers and public health agencies.
In addition to its domestic footprint, Curative has established partnerships in Canada and select markets in Europe and Asia, leveraging a network of contract manufacturing organizations and distribution agreements. The company’s offerings extend to direct-to-consumer telehealth services, at-home testing kits and custom assay development for pharmaceutical and life science clients. Curative’s supply chain capabilities support both large-scale public health initiatives and boutique clinical trial programs.
Under the leadership of CEO Dr. Isaac Turner, a serial entrepreneur with a background in biomedical engineering, Curative’s executive team combines expertise in clinical diagnostics, regulatory affairs and commercial strategy. The board includes seasoned professionals in laboratory medicine and digital health, guiding the company’s expansion into next-generation diagnostic technologies. Curative continues to invest in research and development, targeting multiplex assays and automation solutions to address evolving global health challenges.
AI Generated. May Contain Errors.
